The European Medicines Agency has issued draft guidelines for biosimilars that allow for the use of non-European reference products in limited circumstances "to avoid unnecessary repetition of clinical trials." The new guidelines are a revision of 2005 regulations and are meant to define the principles for establishing biosimilarity. The EMA draft is open for industry comment until the end of October.

Related Summaries